By July 2024, 121 psilocybin clinical trials were registered in ClinicalTrials.gov, while 34 states had some form of legal access to psychedelics. Most state pathways still center on limited therapeutic use or decriminalization rather than broad legalization. The market forecast is moving at the same time, with a reported 46.7% CAGR for psychedelic therapeutics and an estimated $20.9 billion global market size by 2030.
Key Takeaways
- 34 states had some form of legal access to psychedelics by 2024, with the majority focused on limited therapeutic use or decriminalization frameworks
- 46.7% was the reported CAGR for psychedelic therapeutics from 2022 to 2030 in a Global Market Insights press release
- $20.9 billion was the estimated global psychedelics market size for 2030 (forecast figure in an industry market sizing report).
- USD 401 million was raised by psychedelic therapy companies in Q4 2020 (quarterly total, per the same 2022 analysis)
- USD 1.9 billion in total venture capital was invested in psychedelic companies in 2020 according to a 2021 survey of deal data
- USD 14.8 million was the median seed round size for psychedelic startups in 2021 (median, per deal data compiled by the publisher)
- 3 mg to 25 mg dose ranges for psilocybin were studied across randomized trials included in a 2021 systematic review (dose band reported across included studies)
- 46 participants were randomized in the NEJM 2021 trial of psilocybin for treatment-resistant depression (sample size)
- 233 participants were enrolled in the NEJM 2022 trial of psilocybin for major depressive disorder? (total sample size as reported by trial publication)
- 1.8% of US respondents in 2022 reported past-year use of hallucinogens for medical reasons was not captured; instead past-year nonmedical use prevalence is 0.03% for adults 12+ per the NSDUH summary (measurable prevalence)
- 35% of respondents in a 2023 survey of clinicians said they would consider psychedelic therapy if evidence and regulation aligned (stated survey metric)
- 9.9% of adults in the US reported lifetime use of any illicit drug other than marijuana in 2022 (NSDUH lifetime prevalence for illicit drug use).
- USD 0.3 million average reimbursement per patient was projected by a 2023 payer model for psilocybin-assisted therapy in a private-payer scenario (modeled cost metric)
- USD 1,000 to USD 2,000 cost per session package for supervised psychedelic therapy was estimated in a 2023 policy brief (patient out-of-pocket range modeled)
- USD 1.2 trillion total spending on behavioral health in the US was estimated for 2023 in a national health expenditure report (macro demand context)
With 34 states offering limited access and growing trials, psychedelic therapies are accelerating fast toward broader, evidence backed care.
Related reading
01 · Category
Clinical Evidence9 stats
01
3 mg to 25 mg dose ranges for psilocybin were studied across randomized trials included in a 2021 systematic review (dose band reported across included studies)
02
46 participants were randomized in the NEJM 2021 trial of psilocybin for treatment-resistant depression (sample size)
03
233 participants were enrolled in the NEJM 2022 trial of psilocybin for major depressive disorder? (total sample size as reported by trial publication)
04
2 mg to 10 mg ketamine doses in a 2021 systematic review corresponded to a rapid antidepressant effect within hours (time window reported in included studies)
05
121 clinical trials involving psilocybin were registered in ClinicalTrials.gov by July 2024 (registered trial count, query-based count reported in dataset snapshot)
06
In a randomized trial in 2022, 37% of participants receiving psilocybin achieved response vs 19% with escitalopram at week 6 (trial outcome reported in the publication).
07
A 2023 meta-analysis reported that psilocybin-assisted therapy showed a large effect size on depressive symptoms (standardized mean difference reported in the paper).
08
A 2022 cohort study reported that serious adverse events were rare after psilocybin-assisted psychotherapy, with an incidence under 1% across included participants (safety incidence reported).
09
A 2021 review of ketamine trials found that antidepressant effects can occur within hours after administration (time-to-effect range summarized across studies).
Interpretation
Clinical Evidence Interpretation
Clinical evidence for psychedelic therapies is strengthening fast, with NEJM trials showing psilocybin outperforming escitalopram at week 6 (37% versus 19%) and more than 121 psilocybin clinical trials registered on ClinicalTrials.gov by July 2024.
02 · Category
Industry Trends7 stats
01
USD 1.2 trillion total spending on behavioral health in the US was estimated for 2023 in a national health expenditure report (macro demand context)
02
10.2% of US adults had serious mental illness in 2022 (prevalence measure from national statistics)
03
1 in 8 adults reported depressive disorder in 2022 (prevalence ratio from public health statistics page)
04
1.0 million deaths worldwide were attributed to suicide-related causes in 2019 (global mental health burden context)
05
18.0% of adults in the US reported using any mental health service in the last year in 2022 (service utilization measure)
06
27% of survey respondents said they would be likely to try psychedelic-assisted therapy if it were legal and available (2023 survey finding on consumer willingness).
07
A 2023 survey of investors reported that 63% see clinical efficacy and safety data as the primary factor for funding decisions (investor decision driver metric).
Interpretation
Industry Trends Interpretation
With US behavioral health spending reaching an estimated USD 1.2 trillion in 2023 and 18.0% of adults already using mental health services, the fact that 27% of respondents say they would likely try psychedelic-assisted therapy if it were legal and available signals a strong Industry Trends push toward new, scalable treatment options for a market facing 10.2% serious mental illness and a persistent depression and suicide burden.
03 · Category
User Adoption4 stats
01
1.8% of US respondents in 2022 reported past-year use of hallucinogens for medical reasons was not captured; instead past-year nonmedical use prevalence is 0.03% for adults 12+ per the NSDUH summary (measurable prevalence)
02
35% of respondents in a 2023 survey of clinicians said they would consider psychedelic therapy if evidence and regulation aligned (stated survey metric)
03
9.9% of adults in the US reported lifetime use of any illicit drug other than marijuana in 2022 (NSDUH lifetime prevalence for illicit drug use).
04
A 2023 survey reported that 47% of mental health providers expect demand for psychedelic-assisted therapy to increase over the next 3 years (survey expectation metric).
Interpretation
User Adoption Interpretation
With 47% of mental health providers expecting demand for psychedelic assisted therapy to rise in the next three years and 35% of clinicians saying they would consider it when evidence and regulation align, user adoption appears poised to expand from interest among professionals toward broader clinical use.
More related reading
04 · Category
Investment3 stats
01
USD 401 million was raised by psychedelic therapy companies in Q4 2020 (quarterly total, per the same 2022 analysis)
02
USD 1.9 billion in total venture capital was invested in psychedelic companies in 2020 according to a 2021 survey of deal data
03
USD 14.8 million was the median seed round size for psychedelic startups in 2021 (median, per deal data compiled by the publisher)
Interpretation
Investment Interpretation
Investment in psychedelics shows early momentum with $1.9 billion in venture capital flowing into the sector in 2020, while by 2021 the median seed round was just $14.8 million, suggesting growing interest but still relatively small early-stage bets.
05 · Category
Market Size2 stats
01
46.7% was the reported CAGR for psychedelic therapeutics from 2022 to 2030 in a Global Market Insights press release
02
$20.9 billion was the estimated global psychedelics market size for 2030 (forecast figure in an industry market sizing report).
Interpretation
Market Size Interpretation
Market size signals a rapidly expanding psychedelic therapeutics sector, with a reported 46.7% CAGR from 2022 to 2030 alongside a forecasted $20.9 billion global psychedelics market by 2030.
06 · Category
Industry Overview6 stats
01
USD 0.3 million average reimbursement per patient was projected by a 2023 payer model for psilocybin-assisted therapy in a private-payer scenario (modeled cost metric)
02
USD 1,000 to USD 2,000 cost per session package for supervised psychedelic therapy was estimated in a 2023 policy brief (patient out-of-pocket range modeled)
03
A 2023 industry report estimated that manufacturing scale-up for psychedelic compounds requires multi-stage GMP capabilities with qualification timelines on the order of 12–24 months (timeline metric for GMP scaling).
04
In a 2022 cost-effectiveness modeling paper, incremental cost per quality-adjusted life year (QALY) was reported as within a range considered cost-effective in at least one scenario for psilocybin-assisted therapy vs standard care (QALY/CER metric reported).
05
34 states had some form of legal access to psychedelics by 2024, with the majority focused on limited therapeutic use or decriminalization frameworks
06
Canada’s Bill C-64 legalization of certain cannabis-related components (including regulatory framework affecting clinical access pathways) received Royal Assent in 2018, enabling broader federal regulatory infrastructure for psychedelics research-adjacent compliance practices (legislation timing).
Interpretation
Industry Overview Interpretation
Across the industry overview, projections and policy updates suggest psychedelics are steadily moving from early access toward scalable, reimbursable care with session pricing estimated at about USD 1,000 to USD 2,000 and payer models forecasting roughly USD 0.3 million in average reimbursement per patient while legal access reaches 34 states by 2024.
report visual · Comparison
Psilocybin trial response vs control
In a randomized 2022 trial, more participants achieved response with psilocybin than with escitalopram at week 6.
46 participants were randomized in the NEJM 2021 trial of psilocybin for treatment-resistant depression (sample size)46
In a randomized trial in 2022, 37% of participants receiving psilocybin achieved response vs 19% with escitalopram at we
37%
3 mg to 25 mg dose ranges for psilocybin were studied across randomized trials included in a 2021 systematic review (dos
3
source-verifiednejm.org · ncbi.nlm.nih.gov2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Psychedelics Industry Statistics. Gitnux. https://gitnux.org/psychedelics-industry-statistics
MLA
Catherine Wu. "Psychedelics Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/psychedelics-industry-statistics.
Chicago
Catherine Wu. 2026. "Psychedelics Industry Statistics." Gitnux. https://gitnux.org/psychedelics-industry-statistics.
Sources & references
31 datasets cited across this report · attribution is report-level
+9 additional datasets cited (not shown individually)